92 related articles for article (PubMed ID: 21186399)
1. Elevated expression of orexin receptor 2 (HCRTR2) in benign prostatic hyperplasia is accompanied by lowered serum orexin A concentrations.
Malendowicz W; Szyszka M; Ziolkowska A; Rucinski M; Kwias Z
Int J Mol Med; 2011 Mar; 27(3):377-83. PubMed ID: 21186399
[TBL] [Abstract][Full Text] [Related]
2. Effects of changes in energy homeostasis and exposure of noxious insults on the expression of orexin (hypocretin) and its receptors in the brain.
Machaalani R; Hunt NJ; Waters KA
Brain Res; 2013 Aug; 1526():102-22. PubMed ID: 23830852
[TBL] [Abstract][Full Text] [Related]
3. Orexin B inhibits proliferation and stimulates specialized function of cultured rat calvarial osteoblast-like cells.
Ziolkowska A; Rucinski M; Tyczewska M; Malendowicz LK
Int J Mol Med; 2008 Dec; 22(6):749-55. PubMed ID: 19020772
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of NKX3.1 in benign prostatic hyperplasia.
Irer B; Toylu A; Aslan G; Celebi I; Yorukoglu K; Atabey N
Urology; 2009 May; 73(5):1140-4. PubMed ID: 18597829
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
[TBL] [Abstract][Full Text] [Related]
7. Interferon-gamma and its functional receptors overexpression in benign prostatic hyperplasia and prostatic carcinoma: parallelism with c-myc and p53 expression.
Royuela M; de Miguel MP; Ruiz A; Fraile B; Arenas MI; Romo E; Paniagua R
Eur Cytokine Netw; 2000 Mar; 11(1):119-27. PubMed ID: 10705309
[TBL] [Abstract][Full Text] [Related]
8. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues.
Hahn D; Simak R; Steiner GE; Handisurya A; Susani M; Marberger M
J Urol; 2000 Aug; 164(2):506-10. PubMed ID: 10893635
[TBL] [Abstract][Full Text] [Related]
9. Localization of angiotensin-converting enzyme in the human prostate: pathological expression in benign prostatic hyperplasia.
Nassis L; Frauman AG; Ohishi M; Zhuo J; Casley DJ; Johnston CI; Fabiani ME
J Pathol; 2001 Dec; 195(5):571-9. PubMed ID: 11745693
[TBL] [Abstract][Full Text] [Related]
10. The role of orexin A in the control of prolactin and growth hormone secretions in sheep--in vitro study.
Molik E; Zieba DA; Misztal T; Romanowicz K; Wszola M; Wierzchos E; Nowakowski M
J Physiol Pharmacol; 2008 Dec; 59 Suppl 9():91-100. PubMed ID: 19261974
[TBL] [Abstract][Full Text] [Related]
11. Expression of orexin A and its receptor 1 in the bovine urethroprostatic complex.
Russo F; Pavone LM; Tafuri S; Avallone L; Staiano N; Vittoria A
Anat Rec (Hoboken); 2008 Feb; 291(2):169-74. PubMed ID: 18213704
[TBL] [Abstract][Full Text] [Related]
12. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate.
Steiner GE; Newman ME; Paikl D; Stix U; Memaran-Dagda N; Lee C; Marberger MJ
Prostate; 2003 Aug; 56(3):171-82. PubMed ID: 12772186
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical comparative analysis of transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates.
De Miguel P; Royuela ; Bethencourt R; Ruiz A; Fraile B; Paniagua R
Cytokine; 1999 Sep; 11(9):722-7. PubMed ID: 10479409
[TBL] [Abstract][Full Text] [Related]
14. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia.
Soulitzis N; Karyotis I; Delakas D; Spandidos DA
Int J Oncol; 2006 Aug; 29(2):305-14. PubMed ID: 16820871
[TBL] [Abstract][Full Text] [Related]
15. Evidence for activation of the renin-angiotensin system in the human prostate: increased angiotensin II and reduced AT(1) receptor expression in benign prostatic hyperplasia.
Dinh DT; Frauman AG; Somers GR; Ohishi M; Zhou J; Casley DJ; Johnston CI; Fabiani ME
J Pathol; 2002 Feb; 196(2):213-9. PubMed ID: 11793373
[TBL] [Abstract][Full Text] [Related]
16. Identification of orexins and cognate receptors in the lacrimal gland of sheep.
Dall'aglio C; Mercati F; Maranesi M; Boiti C
Peptides; 2012 May; 35(1):36-41. PubMed ID: 22465661
[TBL] [Abstract][Full Text] [Related]
17. Long-lasting up-regulation of orexin receptor type 2 protein levels in the rat nucleus accumbens after chronic cocaine administration.
Zhang GC; Mao LM; Liu XY; Wang JQ
J Neurochem; 2007 Oct; 103(1):400-7. PubMed ID: 17623047
[TBL] [Abstract][Full Text] [Related]
18. The physiological role of orexins.
Martynska L; Wolinska-Witort E; Chmielowska M; Bik W; Baranowska B
Neuro Endocrinol Lett; 2005 Aug; 26(4):289-92. PubMed ID: 16135995
[TBL] [Abstract][Full Text] [Related]
19. INSL3 in the benign hyperplastic and neoplastic human prostate gland.
Klonisch T; Müller-Huesmann H; Riedel M; Kehlen A; Bialek J; Radestock Y; Holzhausen HJ; Steger K; Ludwig M; Weidner W; Hoang-Vu C; Hombach-Klonisch S
Int J Oncol; 2005 Aug; 27(2):307-15. PubMed ID: 16010410
[TBL] [Abstract][Full Text] [Related]
20. Protease-activated receptor-1 upregulates fibroblast growth factor 7 in stroma of benign prostatic hyperplasia.
Wang W; Zhang X; Mize GJ; Takayama TK
Prostate; 2008 Jul; 68(10):1064-75. PubMed ID: 18386288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
